Bio-Rad Laboratories (NYSE:BIO.B) Hits New 1-Year High – Should You Buy?

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B) hit a new 52-week high on Monday. The stock traded as high as $389.98 and last traded at $389.98, with a volume of 76 shares changing hands. The stock had previously closed at $379.50.

Bio-Rad Laboratories Price Performance

The company has a debt-to-equity ratio of 0.11, a current ratio of 3.18 and a quick ratio of 2.37. The stock’s fifty day moving average is $367.51 and its 200-day moving average is $312.98. The stock has a market cap of $10.43 billion, a PE ratio of 10.27 and a beta of 0.96.

Bio-Rad Laboratories (NYSE:BIO.B) last issued its earnings results on Wednesday, November 4th. The company reported $2.65 EPS for the quarter. Bio-Rad Laboratories had a net margin of 39.45% and a return on equity of 3.58%. The company had revenue of $656.40 million for the quarter.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops and manufactures products for life science research and clinical diagnostics. Founded in 1952, the company serves research institutions, biotechnology and pharmaceutical companies, clinical laboratories, hospitals and other customers around the world.

Its life science business supplies instruments, reagents and software used in areas such as gene expression, protein analysis, cell biology and genomics. Its offerings include PCR and digital PCR systems, electrophoresis products and tools for protein purification and analysis.

Bio-Rad’s clinical diagnostics business provides testing systems, reagents and quality-control products for laboratories.